

## Draft Guidance on Flavoxate Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

**Active ingredient:** Flavoxate Hydrochloride

**Form/Route:** Tablets/Oral

**Recommended studies:** 1 study

Type of study: Fasting

Design: Single-dose, two-way crossover *in-vivo*

Strength: 100 mg

Subjects: Normal healthy males and females, general population

Additional Comments:

---

**Analytes to measure (in appropriate biological fluid):** Flavoxate and the metabolite, 3-methyl-flavone-8-carboxylic acid in plasma.

**Bioequivalence based on (90% CI):** Flavoxate or the metabolite, 3 methyl-flavone-8-carboxylic acid. If flavoxate can be reliably measured, a confidence interval approach for bioequivalence determination should be used for flavoxate. If flavoxate cannot be reliably measured, a confidence interval approach for bioequivalence determination should be used for 3-methyl-flavone-8-carboxylic acid.

**Waiver request of in-vivo testing:** Not Applicable

### Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.fda.gov/cder/ogd/index.htm>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.